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Development of Dual Enzyme and Oxidation-responsive Drug Delivery Systems 
 
Sung Hwa Hong 
 
 Conventional chemotherapy using small molecular weight anticancer drugs presents many 
side effects due to poor specificities and aqueous solubility. To overcome the limitations, polymer-
based drug delivery systems (PDDS) have been emerged for targeted delivery of therapeutic 
agents. Upon introduction of stimuli-responsive platform, the drugs can be released in controlled 
manner at the targeted tumor site providing enhanced drug efficacy and reduced toxicity. Stimuli-
responsive degradation platform involves incorporation of covalent linkages that can be cleaved 
in response to external stimuli. The external stimuli can be found in altered microenvironment in 
pathophysiological tissues. For example, elevated levels of esterase and reactive oxygen species 
(ROS) are found in cancer tumor cells. As esters can be cleaved by the esterase and sulfides can 
be oxidized by the ROS, esters and sulfides can be incorporated to polymer to exhibit esterase and 
oxidation-responsive properties.  
Size is an important consideration for the design of drug delivery systems. Ideally, the size 
should be ranged from 50 to 150 nm for optimal biodistributions and targeting ability. Microfluidic 
process provides high degree of control over the size of NPs. Chapter 2 examines size tunability 
of the dual enzyme- and oxidation-responsive polyester-based nanoparticulates (DPE-NPs) using 
a microfluidic instrument for cancer therapy. The DPE-NPs can be fabricated by using the 
polyester and polymeric stabilizer. The size of NPs can be influenced by changing the variables 
such as microfluidic parameters (total flow rate and organic/aqueous flow rate ratio) and 
formulation parameters (molecular weight of polyesters, concentration of nanoparticles, and nature 
and amount of stabilizers). In addition to size of NPs, it turns out that these parameters have an 
effect on colloidal stability. The results obtained from dual stimuli-responsive degradation and in 
vitro experiments with an enhanced cellular uptake demonstrate that the DPE-NPs can offer a 
versatile platform for the development of drug delivery systems. 
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Chapter 3 describes biological assessment of DPE-NPs as effective tumor-targeting 
intracellular nanocarriers. Doxorubicin (Dox), a clinically used anticancer drug, was incorporated 
into DPE-NPs stabilized with PEG and Brij S20. They exhibited excellent colloidal stability and 
as well as in pseudo-physiological conditions without any aggregation. They were destabilized in 
response to esterase that cleaved ester linkages and to hydrogen peroxide that oxidized sulfides. 
Such disruption led to an enhanced release of encapsulated therapeutics. For biological 
perspectives, the DPE-NPs were assessed in vitro using HeLa cervical cancer cells as a model. The 
results from MTT assay, epifluorescence microscope, flow cytometry, and cellular entry assay 
suggest that the dual responses triggered the intracellular release of the Dox to prohibit the cell 
proliferation followed by a rapid internalization through caveolae-mediated endocytosis. Further 
evaluation on 3D HeLa multicellular tumor spheroid (MCTS) indicated that the penetration ability 
of Dox was significantly enhanced when encapsulated in DPE NPs, suggesting that such deep 
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Chapter 1                                                                                               
Introduction 
 
1.1 Overview of research and goals 
My Master’s research aims to fabricate polyester-based (DPE) nanocarriers and to explore 
dual enzyme and oxidation-responsive degradation. The DPE designed to have both ester and 
sulfide linkages in the backbone, was synthesized by a click-type thiol-ene Michael addition 
reaction. Due to its hydrophobicity, the polyester formed colloidally-stable nanoparticles with an 
aid of stabilizers. The resulting nanoparticulates underwent polarity change or main chain degradation 
upon dual responses, leading to enhanced release of encapsulated anticancer drugs in targeted cells. 
Further, they were evaluated in vitro as intracellular nanocarriers for cancer therapy exhibiting an 
enhanced release of anti-cancer drugs (Doxorubicin).  
1.2 Polymer-based drug delivery systems 
As a counter-measure to cancer, chemotherapy has long been used as a means of treatment 
due to its ability not only to kill cancer cells, but also, to prevent the spread of cancer throughout 
the body. However, conventional chemotherapy presents several issues.1-3 One issue involves the 
poor solubility of drugs in aqueous environment. The poorly-soluble molecules are subjected to 
be removed by reticuloendothelial systems, resulting in a limited circulation time in the body.4, 5 
To achieve therapeutic effect, an increase in the dose of drug is required. The other issue is the 
rapid clearance from the body which limits drug efficacy. Drugs with small molecular weights 
(diameter < 5 nm or molecular weight < 45 kDa) are subjected to be removed by kidney filtration.6 
Another issue involves cytotoxicity that is not only limited to cancer cells, but also, normal healthy 
cells.3  
To overcome the limitations of small molecular weight therapeutics, polymer-based drug 
delivery systems (PDDS) have been emerged as promising candidates for advanced cancer therapy. 
Small molecular weight drugs can be incorporated in nanocarriers to be carried to cancer tissues. 
Nanocarriers’ targeting ability is due to the rapid growth of cancer tissues compared to normal 
tissues. Maeda et al. claimed that cancer tumors have leaky vasculatures where macromolecules 
can be extravasated due to tight lymphatic capillaries allowing for the accumulation of nanocarriers 
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(Scheme 1.1).7 On the other hand, nanocarriers could not be infiltrated into normal tissues due to 
tight endothelial cell lines and functional lymphatic drainage systems. This phenomenon is so-
called the enhanced permeability and retention (EPR) effect facilitates the development of passive 
targeted drug delivery systems. In addition, PDDS enable the enhancement of pharmacokinetics 
and biodistributions of the small molecule drugs thereby increasing the therapeutic efficacy and 
minimizing the side effects.3 Further, nanocarriers have been designed to provide a stealth effect 
(bypassing biological barriers), thus reducing side effects common to small drugs and enhancing 
circulation half-life.8-11 
The performance of the nanocarriers to exhibit these features are dependent on the size of 
the nanocarriers. Small nanocarriers below 10 nm are subjected to be removed by glomerulus 
filtration whereas large nanocarriers, in micrometer range, lack the ability to accumulate in the 
tumor.12 For cancer targeting drug delivery system, nanocarriers with hydrodynamic radius of 50 
nm to 200 nm are considered optimal to avoid clearance by the body and to effectively extravasated 
and accumulated in tumor sites.4, 5, 13 Moreover, the size affects other features of nanocarriers such 
as the release kinetics of the encapsulated drug; larger particles tend to have smaller initial burst 
release and sustained release.14 
 






1.3 Polyesters in DDS  
The use of polymers had a dramatic impact in the landscape of oncology. The most widely 
explored polymers are polyesters, typically poly(ɛ-caprolactone) (PCL), polylactide (PLA), 
poly(lactide-coglycolide) (PLGA) and poly(trimethylene carbonate) (PTMC). Their popularity 
can be attributed to three of their properties: biocompatibility, biodegradability and tunability.  
First, biocompatibility is one of the most important criteria to evaluate biomaterials.15  The 
aforementioned polyesters are ideal biomaterials because they are determined to be non-toxic, non-
immunogenic and provoke no other diseases. Furthermore, the polyesters do not react with the 
most of encapsulated drugs. For instance, PLA has been widely used for clinics followed by the 
FDA approval, demonstrating the safety of the PLA for biomedical applications.16 Second, 
biodegradability is an important consideration. Biodegradable polyesters retain their structures 
until they complete their role and degrade to smaller molecules that can be readily removed from 
the body. For example, PLGA is degraded chemically by hydrolytic cleavage of ester linkages in 
the backbone producing lactic acid and glycolic acid. These products are water soluble and non-
toxic. They can be removed by the body through renal clearance or metabolized to carbon dioxide 
and water through the tricarboxylic acid cycle.17, 18 Third, polyesters can be modified to affect 
certain features of nanoparticles. For instance, a PEG-PCL diblock copolymer was synthesized via 
ring opening polymerization for breast cancer treatment.19 In this system, the PCL component of 
the micelle enables the encapsulation of Dox (Doxorubicin) while the PEG component provides 
stealth effect to avoid immune response and long circulating half-life in the body. 
 
1.4 Stimuli-responsive degradation (SRD) systems 
Conventional drug delivery systems show slow and uncontrolled release kinetics of 
encapsulated drugs. Stimuli-responsive degradation (SRD) systems (so-called smart or intelligent 
drug delivery systems) have been emerged as a promising platform for drug delivery to overcome 
the limitations of sustained and uncontrolled release of drug from drug delivery systems.20-22 SRD 
involves the introduction of dynamic covalent linkages into the design of polymers. To integrate 
SRD platforms for PDDS, a fundamental understanding of physiological and pathophysiological 
environments are necessary; the differences can be utilized to design more specific drug delivery 
systems towards cancer tumor tissues.  
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As illustrated in Figure 1.1, external stimuli include endogenous stimuli such as pH,23 
glutathione (GSH),24 reactive oxygen species (ROS),25 and enzymes26 and exogenous stimuli such 
as light,27 temperature,28 and magnetic field.29 The major advantage of SRD polymers is to enable 
the release of cargoes only when specific trigger is present. Therefore, the timing and the duration 
of drug release can be adjusted.   
 
 
Figure 1. 1. Illustration of variety of stimuli triggers30 (a) and cleavable linkers that have been 
used for stimuli-responsive drug delivery systems31 (b). 
 
1.4.1 Enzyme-responsive DDS 
 Enzymes play important roles as biological catalysts in the body. They can act on specific 
substrates, functional groups, or specific molecules in physiological and metabolic processes. The 
enzymatic activities are necessary for physiological homeostasis and therefore dysregulation of 
enzyme expressions are often associated with many diseases including cancer.32-36 Such 
overexpressed enzymes serve as particularly promising biomarkers.  
 Given the promise of enzymes, various types of enzyme-responsive PDDS have been 
developed for controlled release of drugs. Most systems contain covalent linkages that are 
susceptible to be cleaved by enzymes. Upon cleavages, polymeric nanoparticles can degrade or 
disassemble to release the encapsulated therapeutics.37, 38 Two main strategies have been 
developed. One strategy involves introduction of enzymatically labile linkages to polymer 




and react with specific enzymes. This section highlights the advances in enzyme-responsive 
polymeric nanoparticles using two strategies. 
1.4.1.1 Hydrolase-responsive polymers 
In this strategy, polymers are rendered enzyme-sensitive as they have labile moieties in the 
backbone or side chain that can be cleaved by enzymes. Proteases, glycosidases, and esterases are 
classified as the subclass of hydrolases and they have been utilized as biomarkers due to their 
abundance in diseases.39 A several polymeric nanoparticles have been synthesized targeting 
different enzymes such as acid phosphatase (APase), penicillin G admidase (PGA) and porcine 
liver esterase (PLE). The design of the APase, PGA, and PLE-responsive polymers involves 
incorporation of phosphate group, amide group and ester group, respectively.  
For example, APase-responsive double hydrophilic diblock copolymer have been 
synthesized via nitroxide-mediated polymerization.40 The diblock copolymer contains PEG block 
and phosphorylated poly(4-vinylphenol) block, yielding water soluble polymer due to the 
hydrophilicity of PEG and phosphate group. Upon the cleavage of the phosphate group in the 
presence of APase, the polymer turns to an amphiphilic block copolymer because of the 
hydrophobicity of the resulting poly(4-vinylphenol) block. Subsequently, this amphiphilic block 
copolymer spontaneously form spherical micelles with an average diameter of 90 nm by 
transmission emission microscopy (TEM) (Figure 1.2a). The analysis by 31P NMR indicates that 
the enzymatic dephosphorylation was slow and some amount of phosphate remained unreacted 
even after 11 days of incubation with APase at 0.13 mg/mL. Such slow reaction is attributed to the 
formation of micelles before the cleavage of all the phosphate groups. This work shows great 
potential of polymeric assemblies as drug delivery systems since their physical and chemical 
characteristics can be modulated enzyme reactions. 
In another study, hydrophobic dendrons have been functionalized with PGA-cleavable 
phenyl acetamide groups on the end groups stabilized and attached to PEG (Figure 1.2b).41 The 
cleavage of the acetamide groups produces amines that are protonated in a physiological pH. The 
decrease in amphiphilicity triggered the disassembly of micelles, resulting in the release of 
encapsulated cargoes. On the other hand, they were stable in the presence of PLE (that cleaves the 
ester bonds) demonstrating their specificities. These results were supported by the decrease in 
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fluorescence intensity of the Nile red encapsulated in the micelles and by the disappearance of the 
peaks corresponding to amphiphilic hybrids in the HPLC. These results suggest the accumulation 
of partially degraded micelles. The fully degraded tetra-amine hybrid was not observed at the 
relatively low enzyme concentration (0.14 µM) or high enzyme concentration (1.4 µM) over time.  
Figure 1. 2. Schematics of enzymatic activation of water soluble diblock copolymer to produce 
amphiphilic diblock copolymer that can self-assemble40 (a) and enzyme-responsive release of 
hydrophobic guests (drugs) from the micellar nanocarriers41 (b). 
 
The same group has reported esterase-responsive PEG-dendrons consisting of hydrophobic 
PLE-responsive esters attached to PEG groups.42 They studied the drug release kinetics by 
physically encapsulating the coumarin (hybrid 1) or by covalently attaching the coumarin (hybrid 
2). The hybrid 1 displayed complete degradation within 2.5 h in the presence of 2.3 µM of PLE 
whereas the hybrid 2 achieved it after 160 h. All the ester groups were cleaved in the presence of 
PLE. This type of system could be advantageous since the enzyme-sensitive groups in the 
mainchain of the polymeric micelles can be degraded into small molecules that can be easily 
removed by the body followed by the delivery of the encapsulated drug.   
1.4.1.2 Polymers labeled with enzyme-responsive peptides 
Peptides have been incorporated in various ways to target different disease-associated 
enzymes such as matrix metalloproteinases (MMP), cathepsin B and elastase. One of the enzymes 
that are overexpressed in cancer tissues is MMP-2, a type of MMPs.43-46 MMP-2 is a class of 
endopeptidases that can recognize and cleave specific peptide bonds. Therefore, substrate peptides 
of the MMPs can be utilized as enzyme-sensitive moieties in the synthesis of polymeric 




polymerization of L-lactide initiated with a peptide containing MMP-2-responsive site (Pro-Leu-
Gly-Leu-Ala-Gly sequence).47 Its nanoparticles with chemotherapeutic agent (5-Fluoruracil), 
show enhanced cytotoxicity with C2C12 cells expressing MMP-2.48 Selectivity of the MMP was 
demonstrated by synthesizing the same polymer with a different peptide sequence. This control 
experiment did not indicate any cleavage in the peptide linkages. Another group has targeted 
MMP-2 using synthesized diblock copolymer nanoparticles.49 The nanoparticles consist of 
Paclitaxel, an anticancer drug, conjugated to the hydrophobic block and peptide, containing MMP-
2 responsive sequence in L-configuration, to the hydrophilic block (Figure 1.3a). The nanoparticles 
with peptide in L configuration (NPL) proved significant enhancement of therapeutic efficacy in 
vivo. Contrarily, their control experiment with peptide sequence in D-configuration (NPD) 
demonstrated accumulation of micelles in the targeted tissues but without any recognizable 
therapeutic effect (Figure 1.3c). Compared to paclitaxel, NPL exhibited similar degree of tumor 
growth inhibition with an improved biocompatibility in healthy mice (Figure 1.3b).  
 
Figure 1. 3. Preparation of MMP-responsive nanoparticles (a). Toxicity of paclitaxel-loaded 
nanoparticles in healthy mice at the maximum tolerated dose (b) and effective inhibition of 







  Cathepsin B has been selected as a biological cue for drug delivery systems. Cathepsin B 
is a lysosomal cysteine protease that is abundant in the intracellular compartment of cancer cells.50-
52 The substrate peptide (Gly-Phe-Leu-Gly, GFLG), has been used for the development of 
cathepsin B-responsive materials. For example, peptide dendrimer drug conjugate (PEGylated 
dendron-GFLG-Dox) was synthesized by a copper catalyzed alkyne-azide two-step click 
reaction.53 Drug release of conventional polymer-drug conjugate has been reported to be slow 
mechanism due to high steric hindrance.54-56 To increase the rate of drug release, Dox was attached 
to GFLG where this peptide can be cleaved to activate Dox. The resulting nanocarriers show an 
enhanced Dox release, which is cleaved from peptide. The performance of the formulation was 
significantly increased in terms of antitumor activity compared to the free Dox in vivo at an equal 
dose.   
Another enzyme that is excessively secreted in the diseased site is elastase.57, 58 Elastase is  
known to break down peptide bonds of the small amino acids such as Ala-Ala bond.59 Elastase-
sensitive polymer-peptide diblock copolymer was synthesized by a combination of N-
carboxyanhydride ring-opening polymerization and nitroxide-mediated radical polymerization.60 
Polystyrene or poly(n-butyl acrylate) was used as hydrophobic block. The polypeptide consists of 
L-glutamic acid and of various quantities of L-alanine. The resulting polymer self-assembles to 
form micelles which were destabilized in response to the elastase. The rate of disassembly was 
controlled with the amount L-alanine content in the polypeptide. The results demonstrate the 
tunability and selectivity of enzyme-sensitive systems to achieve both spatial and temporal control 
of the drug release.  
1.4.2 Oxidation-responsive DDS 
ROS, chemically reactive species, are produced in the body. Typical examples of ROS 
include superoxide (O2
-), hydrogen peroxide (H2O2), hydroxyl radical (●OH), hypochlorite ion 
(OCl-). These ROS play an important role in cellular signaling pathways.61 Under healthy 
physiological condition, ROS levels are controlled through the generation of ROS scavenging 
species, such as GSH.62, 63 Upregulated ROS could cause cell deaths or cellular damages. On the 
other hand, high level of ROS could be found in pathological conditions. In the case of cancer 
cells, they can survive at the higher concentration of ROS and their ROS level is 10 to 100-fold 
higher than that in normal cells.69, 70 The distinct concentration can be an attractive trigger for the 
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development of drug delivery systems. 64, 65 64, 6564-66,71,72 Consequently, ROS-responsive materials, 
or oxidation-responsive materials, have been synthesized oxidizable groups such as sulfides and 
boronic esters. These materials can be categorized based on two mechanisms: solubility switch 
mechanism and degradation mechanism.  
1.4.2.1 Solubility switch mechanism 
Sulfide (or thioether) containing polymeric biomaterials are an example of ROS-responsive 
materials by solubility switch mechanism. Under oxidative environment, hydrophobic sulfide 
groups can be converted to hydrophilic sulfoxide and to sulfone group.66 For example, Gupta et al. 
synthesized and characterized diblock copolymer of propylene sulfide and N,N-
dimethylacrylamide (poly(PS-b-DMA)) through the reversible addition-fragmentation chain 
transfer (RAFT) polymerization.67 Poly(PS-b-DMA) micelles were formed by solvent evaporation 
method and the diameter was determined to be 99 nm by DLS. After 24 hrs of incubation with 
H2O2 (3.3 vol %), the size of micelles decreased to 5 nm in diameter. To further evaluate oxidation-
triggered release, they incorporated fluorescent dye, Nile Red, into the micelles (Figure 1.4). They 
exhibit more rapid release at the relatively high concentration of H2O2 and slower release at the 
lower concentration. In another study, a sulfide-containing diblock copolymer consisting of PEG 
block and 2-(methylthio)ethyl glycidyl ether block has been synthesized by anionic ring opening 
polymerization.68 As shown in Figure 1.4, both DLS and 1H-NMR results show the disassembly 
of micelles as a consequence of oxidation of sulfide to sulfoxide and to sulfone in the presence of 




Figure 1. 4. Illustration of micelle formation of PEG-b-PMTEGE and the disassembly upon 
treatment with H2O2 (a) and the 
1H NMR spectra before (top) and after oxidation with H2O2 
(middle) and NAOCl (bottom) (b).68 
 
1.4.2.2 Degradation mechanism 
Boronic ester groups are an example of degradable ROS-responsive materials. Aryl boronic 
ester group can be oxidized to initiate the quinone methide rearrangement leading to the polymer 
degradation (Figure 1.5b).69-72 For example, new oxidation-responsive polymer bearing aryl 
boronic ester and adipic acid was synthesized through step growth polymerization.72 To vary the 
release rate, two different polymers were synthesized where the aryl boronic ester is either directly 
linked to the polymer backbone or linked to an ether group (Figure 1.5a). Then, Nile red was 
encapsulated in the polymeric micelles through an oil-in-water emulsion technique. Upon 
exposure to H2O2, the release rate of the polymer 2 (with ether linkage) was determined to be an 
order of magnitude more rapid than that of polymer 1 (Figure 1.5c) because H2O2 is more 
accessible to the reactive site. For biological assessment in vitro, activated neutrophil was used to 
create high levels of ROS. The release of the model drug from polymer 2 micelles was twice as 
fast as polymer 1 micelles. In this study, sensitivity of the polymeric assemblies has been 






Figure 1. 5. Chemical structures of polymer 1 and 2 (a). Mechanism of polymer 2 degradation 
upon oxidation by H2O2 (b). Fluorescence of Nile Red upon exposure to H2O2 (c).
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1.5 Scope of this thesis 
My master thesis describes the synthesis and biological assessment of dual ROS and 
esterase-responsive drug delivery systems based on polyesters for cancer therapy. Stimuli-
responsive polyester was synthesized via the facile thiol-ene Michael addition reaction. This 
polyester was used throughout studies in chapter 2 and chapter 3. 
Chapter 2 describes synthesis and size optimization of dual enzyme and oxidation-
responsive polyester-based nanoparticulates (DPE-NPs) formulations. The hydrophobic polyester 
can form nanoparticulates with the aid of biocompatible stabilizers. The sizes of the 
nanoparticulates were tuned by employing different fabrication methods such as solvent 
evaporation emulsion method and microfluidics method. For each method, the effects of different 
parameters were studied: formulation parameters (molecular weight of DPE, concentration of NPs, 
nature and amount of stabilizers) and microfluidic parameters (flow rate ratio and total flow rate). 
The enzyme and oxidation-responsive degradations were examined and the cytotoxicity of the 






In chapter 3, a promising formulation of DPE-NPs was assessed in depth as nanocarriers 
for cancer therapy. The enhanced and controlled drug release was examined in the presence of 
H2O2 and esterase. H2O2 can change the hydrophobic/hydrophilic balance of the nanoparticulates 
that can trigger release of encapsulated drugs. In the presence of the esterase, the cleavage of ester 
linkages causes the degradation of polymeric integrity. Two mechanisms lead to the enhanced 
release of encapsulated cargoes. The potential of DPE-NPs as intracellular nanocarriers was 
evaluated in vitro experiments using 2D and 3D cell culture. 
 
Figure 1. 6. Summary of overall projects of esterase and oxidation-responsive polyester-based 
materials. (LDPE and HDPE = low molecular weight and high molecular weight dual enzyme 




Chapter 2                                                                                               
Microfluidic assembly to synthesize dual enzyme/oxidation-
responsive polyester-based nanoparticulates with controlled sizes 
for drug delivery 
 
This chapter reproduced the article published in Langmuir, 2018, 34, 3316-3325 with the 
permission from the publisher. 
 
2.1 Introduction 
Polymer-based drug delivery systems (PDDS) that can deliver therapeutics to disease sites have 
been considered as a promising nanoplatform in pharmaceutical science and biomedical 
research.73-75 Well-designed PDDS can improve the biodistribution of small molecular weight 
drugs in the body, thus enhancing drug efficacy and minimizing side effects. Given the promise of 
PDDS, polymer-drug conjugates (prodrugs),76-78 dendrimers,79 crosslinked nanogels,80-84 and 
block copolymer-based nanoassemblies,85-88 and nanoparticulates89, 90 are the typical examples of 
extensively studied as promising candidates.  
Particularly, nanoparticulates are composed of hydrophobic cores enabling the encapsulation 
of hydrophobic drugs. A conventional method for the fabrication of aqueous nanoparticulates is 
the batch process where a mixture of aqueous solution of stabilizers with organic solution of 
polyesters is subjected to sonication, dialysis, or emulsification. However, conventional batch 
process could be limited in affording control of NP sizes. Indeed, the optimal size of 
nanoparticulates (NPs) for effective drug delivery to biological systems is reportedly 50–200 nm 
in order to reduce undesired side effects while maintaining antitumor activity via the so-called 
enhanced permeability and retention effect.91-94 Microfluidic process utilizing continuous mixing 
of the aqueous and organic solutions in micro-channels of miniature chips has been explored as a 
promising means to the fabrication of various polymer-based nanostructures for drug delivery.95-
97 Microfluidic process enables the fabrication of NPs with their tunable sizes as well as to produce 
well-defined NPs smaller than those by conventional methods achieving their size limit.98, 99 Given 
such features, numerous reports describe self-assembled nanoassemblies,100-103 liposomes,104-107 
microcapsules,36, 108-112 and microgels.113 However, only few reports describe the exploration of 
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microfluidics to fabricate hydrophobic nanoparticulates dispersed with external stabilizers in 
aqueous solutions. 
Polyesters typically hydroxyalkanoic acid-based aliphatic polyesters such as polylactide and 
its copolymers have been mostly used as hydrophobic core-forming polymers for the fabrication 
of polyester-based nanoparticulates (PENPs).114, 115 However, a critical challenge of 
conventionally-designed aqueous PENP colloids is the slow and uncontrolled release of 
encapsulated drugs in targeted sites. Such slow release is attributed to delayed diffusion of 
hydrophobic drugs through nanopores in hydrophobic cores.116 Stimuli-responsive degradation 
(SRD) is a promising platform that involves the incorporation of stimuli-responsive linkages into 
the design of PDDS. In response to external stimuli, preferably cellular components, these linkages 
can be cleaved or be involved in a change of polarity.3, 117-123 This process causes the disintegration 
or the destabilization of PDDS, thus leading to controlled/enhanced release of encapsulated 
therapeutics. In particular, enzymatic and oxidative reactions are among cellular stimuli that have 
recently received an increasing attention. Enzymes such as esterase to cleave ester linkages124-126 
and oxidants such as hydrogen peroxide as a typical reactive oxygen species127 can be found in 
cellular environments. However, these stimuli have been explored mostly on amphiphilic block 
copolymers in the synthesis of self-assembled nanoassemblies with single response.128-130 To our 
understanding, no reports describe aqueous stabilizer-aided DPE colloids exhibiting dual enzyme 
and oxidation response.  
In this work, we have investigated the microfluidic process for the fabrication of aqueous dual 
stimuli-responsive nanoparticulate colloids with diameters ranging at 50-150 nm. The colloids are 
composed of dual enzyme and oxidation-responsive polyester (DPE) labeled with ester (enzyme 
response) and sulfide (oxidation response) linkages on the backbones that were synthesized by 
polyaddition through a click-type thiol-ene reactions. With a selection of polymeric stabilizers 
including poly(ethylene glycol) and a Pluronic surfactant, microfluidic parameters (total flow rate 
(TFR) and organic/aqueous flow rate ratio (FRR)) as well as formulation parameters (molecular 
weight of DPE, concentration of NPs, nature and amount of stabilizers) were investigated to map 
the tunability of NP sizes. The formed colloids were further characterized for dual stimuli-




2.2 Experimental   
2.2.1 Instrumentation 
1H-NMR spectra were recorded using a 500 MHz Varian spectrometer. The CDCl3 singlet at 
7.26 ppm was selected as the reference standard. Molecular weight and molecular weight 
distribution of DPEs were determined by gel permeation chromatography (GPC). An Agilent GPC 
was equipped with a 1260 Infinity Isocratic Pump and a RI detector. Two Agilent PLgel mixed-C 
and mixed-D columns were used with DMF containing 0.1 mol% LiBr at 50 °C at a flow rate of 
1.0 mL/min. Linear poly(methyl methacrylate) standards from Fluka were used for calibration. 
Aliquots of the polymer samples were dissolved in DMF/LiBr. The clear solutions were filtered 
using a 0.45 m PTFE filter to remove any solvent-insoluble species. A drop of anisole was added 
as a flow rate marker. The size of DPE-NPs in hydrodynamic diameter (by intensity) was measured 
by dynamic light scattering (DLS) at a fixed scattering angle of 175° at 25 °C with a Malvern 
Instruments Nano S ZEN1600 equipped with a 633 nm He-Ne gas laser. Transmission Electron 
Microscopy (TEM) images were obtained using a Philips Tecnai12 TEM, operated at 80kV and 
equipped with a thermionic LaB6 filament. An AMT V601 DVC camera with point to point 
resolution and line resolution of 0.34 nm and 0.20 nm respectively was used to capture images at 
2048 by 2048 pixels. To prepare specimens, the NP dispersions were dropped onto copper TEM 
grids (400 mesh, carbon coated), blotted and allowed to air dry at room temperature. Subsequently, 
uranyl acetate (1%) was applied on the TEM grids and then dried again at room temperature. 
Fluorescence spectra on a Varian Cary Eclipse Fluorescence spectrometer were recorded using a 
1 cm wide quartz cuvette. 
2.2.2 Materials  
2,2’-(ethylenedioxy)diethanethiol (DSH, 95%), ethylene glycol dimethacrylate (EGDMA, 
98%), triethylamine (Et3N, ≥99%), poly(ethylene glycol) (PEG, MW = 6,000 g/mol), Pluronic L-
64 (PL02, MW = 2,900 g/mol), esterase from porcine liver (18 U/mg; one unit will hydrolyze 1 
µmol of ethyl butyrate to butyric acid and ethanol per minute at pH 8.0 at 25 ºC), Nile Red (NR), 
and hydrogen peroxide (H2O2, 30% w/w) from Aldrich, dialysis tubing from Spectrum Labs, 
Dulbecco’s modified eagle medium (DMEM) and fetal bovine serum (FBS) from Wisent, phenol-
red free DMEM from Thermo-Fisher Scientific, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) from Promega were purchased and used as received. 
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2.2.3 Synthesis of DPE 
For the synthesis of HDPE, DSH (3.7 g, 20.2 mmol) was added to a solution consisting of 
EGDMA (4.0 g, 20.2 mmol) and Et3N (565 μL, 4.0 mmol) dissolved in DMSO (13.5 mL) to start 
polymerization. For the synthesis of LDPE, DSH (2.0 g, 10.1 mmol) was added to a solution 
consisting of EGDMA (2.11 g, 11.6 mmol) and Et3N (565 μL, 4.0 mmol) dissolved in DMSO (7 
mL). The reaction mixture for HDPE was stirred at room temperature for 2 days and the reaction 
mixture for LDPE was stirred for 24 hrs. The as-synthesized solutions were precipitated from cold 
methanol to remove excess Et3N and unreacted monomers. The precipitates were isolated by a 
vacuum filtration and dried in a vacuum oven at room temperature for 12 hrs, prior to analysis by 
1H NMR in CDCl3 and GPC. 
2.2.4 Microfluidic preparation of stabilizer-aided NP colloids by nanoprecipitation 
Scheme 2.1a illustrates the fabrication of DPE-NPs using NanoAssemblr Benchtop equipped 
with disposable cartridges (Precision Nanosystems Inc, Vancouver, Canada). Total volume was 
set to 2 mL where the first 0.25 mL was discarded and 1.75 mL of resulting solution was collected 
and analyzed. For fabrication, stock solutions of DPE in acetone at varying concentrations (2- 50 
mg/mL) as well as PL02 and PEG in water at varying concentrations (0.004-5 mg/mL) were 
prepared. As an example to fabricate aqueous HDPE-NP colloids under the microfluidic conditions 
of NP (HDPE+PL02) = 3.8 mg/mL, TFR = 12 mL/min, and FRR = 3/1 (aqueous/organic), an 
organic HDPE solution (14 mg/mL, 0.5 mL) and an aqueous PL02 solution (0.47 mg/mL, 1.5 mL) 
were injected into each inlet, to attain total volume of the resulting dispersion = 2 mL. The resultant 
HDPE-NP dispersions were subjected to dialysis using a dialysis tubing with MWCO = 12 kDa 
against water (1 L) for 4 hrs to remove acetone. To study the effect of TFR and FRR, the 
concentrations and injected volumes of aqueous and organic stock solutions were varied as the 
input parameters for in-suite software of NanoAssemblr Benchtop microfluidic mixer. The size 
and diameter of syringes were fixed. Further experiments were performed with a single sample. 
The reproducibility for microfluidic preparation was examined with the freshly-prepared 
triplicates from a formulation as a typical example shown in Figure A.4. 
Similar procedure was used to fabricate NR-loaded HDPE-NPs with the use of NR (0.4 mg) 
dissolved in acetone with HDPE (2 mg/mL, 1 mL) and PEG (2 mg/mL, 1 mL) under the conditions 
of NP =2 mg/mL, HDPE/PEG  = 1.0 wt/wt, FRR = 1/1, and TFR = 12 mL/min. Followed by the 
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removal of acetone by dialysis against water, resulting NR-loaded dispersion was filtered by using 
0.45 μm PES filter to remove free NR, yielding aqueous NR-loaded NPs.  
2.2.5 Batch preparation of stabilizer-aided NPs with solvent evaporation method 
Generally, a mixture of aqueous stabilizer solution and organic HDPE solution was sonicated 
for 5 min (amplitude = 15 %, 10 sec on, 2.5 sec off) using a digital sonifier (Branson). The resulting 
mixture was kept stirred for 24 hrs at room temperature to remove residual THF, yielding aqueous 
NP dispersion at 2.0 mg/mL. 
2.2.6 Oxidative/enzymatic degradation of NPs 
For oxidation-responsive degradation of NPs in the presence of hydrogen peroxide, aliquots of 
aqueous NP dispersion (0.4 mg/mL, 2.3 mL) were incubated with 1% v/v hydrogen peroxide under 
stirring at room temperature. For enzymatic degradation in the presence of esterase, aliquots of 
aqueous NP dispersion (0.4 mg/mL, 1.7 mL) were incubated with esterase, attaining 10 U. For 
both oxidation/enzymatic degradation, aliquots of NP dispersion (0.4 mg/mL, 1.7 mL) were 
incubated with 1% v/v hydrogen peroxide and esterase, attaining to 10 U. DLS was used to follow 
any changes in size distribution over incubation time. 
2.2.7 Cell culture 
HeLa cervical cancer cells were cultured in DMEM (Dulbecco’s modified Eagle’s medium) 
containing 10% FBS (fetal bovine serum) and 1% antibiotics (50 units/mL penicillin and 50 
units/mL streptomycin) at 37 C in a humidified atmosphere containing 5% CO2. 
2.2.8 Cell viability using MTT assay 
HeLa cells were plated at 5 x 105 cells per well into a 96-well plate and incubated for 24 h in 
DMEM (100 µL) containing 10 % FBS and 1 % antibiotics. Then, they were incubated with 
various concentrations of NPs for 48 h. Blank controls without nanoparticulates (cells only) were 
run simultaneously as control. Cell viability was measured using CellTiter 96 Non-Radioactive 
Cell Proliferation Assay kit (MTT, Promega) according to the manufacturer’s protocol. Briefly, a 
MTT solutions (15 µL) was added into each well. After 4 h incubation, the medium containing 
unreacted MTT was carefully removed. DMSO (100 L) was added into each well in order to 
dissolve the formed formazan purple crystals, and then the absorbance at  = 570 nm was recorded 
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using Powerwave HT Microplate Reader (Bio-Tek). Each concentration was 6-replicated. Cell 
viability was calculated as the percent ratio of the absorbance of mixtures with nanoparticulates to 
control (cells only). 
2.2.9 Live cell imaging  
Stable HeLa cancer cells were plated at 1× 105 cells/well in 35-mm glass-bottom dishes. HeLa 
cells were then washed with PBS three times and phenol red free DMEM medium (0.5 mL) was 
added to the cells. Cells were treated with aqueous NR-loaded NPs or NR solution in acetone to 
make NR = 1 µg/mL and incubated for 4 h at 37 ºC. Live-cells were visualized on a Nikon Eclipse 
Ti, inverted epifluorescence-Lambda XL Microscope equipped with LED Heliophor at 488 nm 
with a Photometrics Evolve EMCCD camera and a 40x/0.95NA objective. Images were acquired 
with NISElements Version 4.0. Images were viewed and analyzed on Image J. 
 
Scheme 2. 1. Digital image of microfluidic cartridge (a) and illustration of microfluidic preparation 
of DPE-NPs using the NanoAssemblr Benchtop (b). 
 
2.3 Results and discussion 
2.3.1 Synthesis of DPEs 
Figure 2.1a illustrates our approach utilizing a base-catalyzed thiol-ene addition to synthesize 
dual enzyme/oxidation-responsive DPE labeled with ester and sulfide linkages on their backbones. 
In the presence of Et3N as a base, the mole ratio of DSH to EGDMA (i.e. thiol and methacrylate 
groups) was varied to synthesize well-defined PEs with two different molecular weights at room 



















the weight average molecular weight) for LDPE and 17 kg/mol with Mw/Mn = 1.5 for HDPE, 
determined by GPC with PMMA standards. 1H-NMR spectrum in Figure 2.1b confirms the 
structure of the purified PEs. 
  
Figure 2. 1. Synthetic scheme through a base-catalyzed thiol-ene reaction to polyesters labeled 
with sulfide and enzyme linkages on the backbones, (a) 1H-NMR spectrum of HDPE in CDCl3 (b) 
and chemical structure of Pluronic and PEG (c). 
 
2.3.2 Design of microfluidic preparation 
The procedure in our experiments includes the preparation of an organic stock solution of DPE 
in acetone and an aqueous stock solution of stabilizers at given concentrations. As illustrated in 
Scheme 2.1b, they were injected to be mixed in the microfluidic channels to form nanoaggregates 
in a mixture of organic solvent and water. In our experiments, acetone (boiling point = 56 C) was 
used as an organic solvent to dissolve DPE. The removal of acetone allows for the preparation of 
colloidally-stable DPE-NPs stabilized with stabilizers in aqueous solution. Two methods to 















Poly(ethylene glycol) (PEG)Pluronic L64 (PL02)
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remove acetone were examined: a dialysis method with dialysis tubing with MWCO = 12 kDa 
over water and a solvent evaporation method to open air in fume hood. HDPE was examined with 
PL02 stabilizer under microfluidic conditions including TFR (total flow rate) = 12 mL/min, and 
FRR (aqueous/organic flow rate ratio) = 3/1. The final concentration of NP (DPE and PL02) was 
designed to be 3.7 mg/mL.  
As compared in DLS diagrams of Figure 2.2, aqueous NPs prepared by two methods had 
monomodal and narrow size distribution as PDI < 0.13. Although a small portion of large 
aggregates is present at less than 4% by intensity in both DLS diagrams, they are negligible by 
volume analysis (<0.1% population). Nevertheless, aqueous NPs prepared by dialysis method had 
diameter = 89 nm, which appeared to be smaller than that (102 nm) for NPs prepared by solvent 
evaporation method by intensity. Further, the dialysis method could remove not only acetone but 
also more importantly excess stabilizers from aqueous dispersion. Consequently, the dialysis 
method was used for our further experiments.  
  
Figure 2. 2. DLS diagrams (by intensity) of HDPE-NPs stabilized with PL02 in aqueous solution 
purified by solvent evaporation method (a) and dialysis (b). Microfluidic conditions: PL02/HDPE 
= 0.1/1 wt/wt, NP = 3.7 mg/mL, TFR = 12 mL/min, and FRR = 3/1. 
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2.3.3 Investigation of microfluidic parameters 
The microfluidic device enables control  over two additional parameters compared to 
conventional solvent evaporation method. TFR depicts the total volume of fluids that are pumped 
into the two inlets at a given time frame. FRR describes volume ratio of the aqueous and organic 
phases. Both TFR and FRR are the important microfluidic parameters that significantly influence 
the mixing rate of organic and aqueous phases in the microchannel, thus the size and size 
distribution of NPs in aqueous solutions.100 Here, the two parameters were examined with both 
HDPE and LDPE in the presence of PL02 stabilizer as the ratio PL02/DPE = 0.1/1 wt/wt. 
TFR was first varied from 2 to 12 mL/min with a fixed FRR = 3/1. Figure 2.3 shows the size 
results. For HDPE NPs, the diameter was 104 nm with TFR = 4 mL/min. It decreased to 94 nm 
when TFR increased to 6 mL/min. Upon the further increase in TFR to 12 mL/min, the diameter 
appeared to be unchanged. For LDPE NPs, the diameter was 137 nm with TFR = 4 mL/min and 
continuously decreased to 118 nm by 20 nm upon further increase of TRP to 12 mL/min. 
Furthermore, the diameters of all HDPE-NPs were smaller than those of all LDPE-NPs at the given 
TFR. For example with TRF = 12 mL/min, the diameter was 96 nm for HDPE-NPs comparable to 
118 nm for LDPE-NPs. Promisingly, all the formed NPs were monomodal with narrow size 
distribution as PDI < 0.1. 
 
 
Figure 2. 3. Sizes and size distributions of aqueous NPs of HDPE (a) and LDPE (b) prepared with 
varying TFRs. Microfluidic conditions: FRR = 3/1, PL02/HDPE = 0.1/1 wt/wt, and NP = 3.7 





























































In another set of the experiments, FRR (here, PL02/DPE ratio) was examined with the fixed 
TFR = 12 mL/min. As seen in Figure 2.4, the diameter increased with an increasing FRR from 1 
to 9. Specifically, the diameter increased largely from 60 to 119 nm by 59 nm for HDPE-NPs, 
while it increased from 111 to 136 nm by 25 nm for LDPE-NPs. An interesting observation was 
that the trend of increasing size with FRR is different from a lipid nanoparticle system based on 1-
palmitoryl-2-oleyl phosphatidylcholine (POPC), which shows the limit size nanoparticle with FRR 
>2.99 Such opposite trend is presumably attributed to different stabilization mechanisms: oil-in-
water emulsion-type polyester nanoparticles stabilized with external stabilizers for our system vs 
self-assembled nanoparticles of lipid amphiphiles. Similar to TFR results, HDPE-NPs had smaller 
diameters than LDPE-NPs prepared under similar conditions. Promisingly, PDI values for both 
HDPE and LDPE-NPs were as low as 0.2, although they appeared to increase with an increasing 
FRR.  
 
Figure 2. 4. Sizes and size distributions of aqueous NPs of HDPE (a) and LDPE (b) prepared with 
varying FRR. Microfluidic conditions: TFR = 12 mL/min, PL02/DPE = 0.1/1 wt/wt, and NP = 3.7 
mg/mL. Note the number on each bar denotes the average diameter. 
 
2.3.4 Investigation of formulation parameters 
Given the results obtained from our investigation on microfluidic parameters, three formulation 
parameters were examined with HDPE: concentration of NPs, nature and amount of stabilizers. 






























































with varying concentrations of NPs (HDPE + stabilizer) under the microfluidic conditions 
including TFR = 12 mL/min and aqueous/organic FRR = 3/1. Overall the diameter increased with 
an increasing concentration of NPs in aqueous solution. Interestingly, it increased step-wise in the 
three ranges of NP concentrations: as low as 1 mg/mL, 4-7 mg/mL, and as high as 14 mg/mL. For 
example, the diameter of HDPE-NPs with PEG stabilizer was 54 nm at 1 mg/mL, 86-93 nm at 4-
7 mg/mL, and 181 nm at 14 mg/mL (Figure 2.5b). The formed HDPE-NPs were monomodal at up 
to 7 mg/mL, but bimodal at 14 mg/mL by intensity (see Figure A.1). The NPs prepared at 1 and 4 
mg/mL concentrations exhibit excellent colloidal stability on shelf with no evidence of 
precipitation over 2 months. However, the NPs prepared at 7 and 14 mg/mL concentrations were 
precipitated after 2 months. No significant effect of stabilizers (PEG and PL02) was observed on 
size and size distribution. 
 
Figure 2. 5. Sizes and size distributions of aqueous HDPE-NPs prepared in the presence of PL02 
(a) and PEG (b) at various NP concentrations. Microfluidic conditions: TFR = 12 mL/min, FRR = 
3/1, and stabilizer/HDPE = 0.1/1 wt/wt. 
 
Figure 2.6 shows the effect of the amount of stabilizers (PL02 and PEG) as the weight ratio of 
stabilizer/HDPE on size and size distribution. When the stabilizer was added up to stabilizer/HDPE 
= 0.5/1 (33 wt%), the diameter decreased to 96 nm with PL02 and 93 nm with PEG. Upon further 
addition of stabilizer as stabilizer/HDPE = 5/1 (83 wt%), the diameter significantly decreased to 
47 nm with PL02 and 67 nm with PEG. Interestingly, HDPE enabled formation of aqueous NPs 


































































absence of stabilizers. This result suggests the formation of aqueous HDPE-NPs with no aids of 
stabilizers through microfluidic process (Figure A.2). The plausible reason is due to the presence 
of two ethylene oxide units in repeating units of polyester backbones, which could retain the 




Figure 2. 6. Sizes and size distributions of aqueous NPs of HDPE prepared in the presence of 
PL02 (a) and PEG (b) at various NP concentrations. Microfluidic conditions: TFR = 12 mL/min, 
FRR = 3/1, and NP concentration = 3.4 g/mL. 
 
2.3.5 TEM for morphology analysis 
TEM was used to get an insight into the morphology of NPs in dried state on carbon grid. 
Figure 2.7 shows the typical TEM image of aqueous HDPE-NPs prepared with PEG/HDPE = 5/1 
wt/wt. Their morphologies appeared to be spherical, with an average diameter to be 60 ± 18 nm, 






































































Figure 2. 7. TEM image of aqueous HDPE-NPs prepared with PEG/HDPE = 5/1 wt/wt. (n = 20) 
 
2.3.6 Comparison with batch process for nanoparticulate preparation 
A batch process involving mixing organic HDPE solution with aqueous stabilizer solution by 
sonication was examined to synthesize a series of HDPE-NPs in the presence of PL02 or PEG 
stabilizers. Figure 2.8 compares the diameter of aqueous HDPE-NPs prepared by microfluidic 
process with batch process at NP = 4 mg/mL as a function of stabilizer/HDPE ratio. Note that 
microfluidic conditions include TFR = 12 mL/min and FRR = 3/1. The result shows that HDPE-
NPs prepared by microfluidic process were smaller than those by batch process under similar 
conditions. As suggested in literature, the smaller size by microfluidic process is attributed to rapid 
mixing of aqueous and organic phases in micro-channels. Similar results were reported on an 





Figure 2. 8. Comparison of the size of aqueous HDPE-NPs prepared by microfluidic process with 
batch process in the presence of varying amounts of PEG (a) and PL02 (b) at NP = 2 mg/mL. 
 
2.3.7 Dual enzyme/oxidation-responsive disassembly 
The formed DPE-NPs contain sulfide and ester linkages in the hydrophobic cores. Their 
responses to enzyme and oxidation were examined using the DLS technique to follow any changes 
in not only size distribution (based on volume) but also Z-ave diameter (based on intensity) (Figure 
2.9). Together with esterase that can cleave ester groups, hydrogen peroxide was selected as a 
typical reactive oxygen species (ROS) along with superoxide, hydroxyl radical, and hypochlorite 
that are found in the body. In the absece of those stimuli, aqueous HDPE-NPs were colloidally 
stable with no change in size distribution. When they were incubated with either 10 U esterase or 
1% hydrogen peroxide individually, they were disintegrated with the occurrence of large 
aggregates over the time. Furthermore, the disintegration of the NPs appeared to be accerelated in 
the presence of both stimuli. As reported, ester bonds can be cleaved in response to esterase,125 
while sulfide bonds can be oxidized to the coresponding more hydrophilic sulfoxides and further 
sulfones by hydrogen peroxide.68, 131  Consequenty, such responses can change the 
hydrophobic/hydrophophilic balance of polyesters, causing the loss of colloidal stability and thus 
destabilization of DPE-NP colloids, resulting in the occurence of large aggregates. These results 
are promising in that such destabilization of the NPs can result in the enhanced release of 











































Figure 2. 9. Evolution of DLS diagrams (volume %) of aqueous HDPE-NPs in the presence of 1% 
hydrogen peroxide (H2O2) (a), 10 U esterase (b), and both stimuli (c), as well as evolution of Z-
ave diameter (by light scattering intensity) at 0.4 mg/mL and pH = 7.2. 
 
2.3.8 Preliminary biological assessment: in vitro cytotoxicity and cellular uptake 
To preliminarily assess the formed aqueous HDPE-NP colloids toward biomedical applications, 
in vitro cytotoxicity with HeLa cells was first examined using a MTT colorimetric assay in the 
presence of NPs prepared with different amounts of PEG and PL02. HeLa cells were cultured and 
incubated with different concentrations of NPs for 48 hrs. Their viability was determined by the 
absorbance ratio of formazan generated with living cells in the presence to absence of NPs (i.e. 
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cells only as controls). As seen in Figure 2.10, NPs prepared without stabilizers had the HeLa 
viability ranging at 40-70% at 100 – 500 g/mL. Promisingly, the viability was enhanced with an 
increasing amount of PEG stabilizer as the increasing ratio of PEG/HDPE wt/wt (Figure 2.10a). 
For HDPE NPs prepared with PEG/HDPE = 5/1 wt/wt, the viability was >80% up to 500 g/mL. 
However, no significant enhancement of the HeLa viability was observed in the presence of PL02 
coatings (Figure 2.10b).  
 
 
Figure 2. 10. Viability of HeLa cancer cells incubated with various amounts of aqueous HDPE-
NPs prepared with different amounts of PEG (a) and PL02 (b) for 48 hrs, determined by a MTT 
assay. 
 
To explore cellular uptake of HDPE-NPs to HeLa cells, Nile Red (NR), a hydrophobic 
fluorophore, was incorporated into NPs. For microfluidic preparation, an organic solution 
consisting of NR and HDPE dissolved in acetone was mixed with an aqueous PEG solution in 
microchannel. The mixture was subjected to dialysis to remove solvent and free (not encapsulated) 
NR that is dissolved in aqueous solution. Most of free NR were precipitated in dialysis tubing due 
to its low solubility in water (<1 µg/ml).132 Those precipitates were removed by filtration with a 
PES filter. Thus, free NR could be completely removed from the mixture by a combined 
purification of dialysis and filtration. The formed NR-loaded NPs had the diameter to be 51 nm by 
DLS (Figure A.3a) and exhibit the strong fluorescence at 622 nm (Figure A.3b). Then, the formed 
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NR-loaded NPs were incubated with HeLa cells and live-cell imaging based on fluorescence was 
conducted to study the internalization of NPs into cells. Figure 2.11 shows the fluorescent images 
of HeLa cells incubated with and without NR-loaded HDPE-NPs, along with free NR as a control, 
for 4 hrs. HeLa cells incubated with NR-loaded NPs and free NR showed strong NR fluorescence 
in their nuclei although the signal was more intense for HeLa cells treated with the NR-loaded NPs, 
compared with free NR. In addition, fluorescence intensity in arbitrary unit was calculated to be 
1202 ± 190 for NR-loaded NPs, which is greater than that 464 ± 144 for free NR. This result 
suggests the rapid internalization of NR-loaded NPs, compared to free NR. 
 
 
Figure 2. 11. Viability of HeLa cancer cells incubated with various amounts of aqueous HDPE-




Colloidally-stable NPs based on dual stimuli-responsive polyesters having enzyme-responsive 






mixing organic DPE solution with aqueous stabilizer solution in micro-channels. The resulting 
NPs had their sizes ranging 50-150 nm in diameter with monomodal and narrow distribution (PDI 
<0.1), confirmed by DLS and TEM measurements. Overall, sizes of DPE-NPs were varied by 
controlling the microfluidic parameters (TFR and FRR) and as well as formulation parameters. 
They were smaller for aqueous HDPE-NPs, compared with LDPE-NPs. With an increasing 
amount of PEG and PL02 polymeric stabilizers, the sizes of NPs decreased; however, no difference 
in sizes was observed with two stabilizers. In comparison with batch process, the microfluidic NPs 
were not only smaller in diameter but also more colloidally-stable (no occurrence of precipitation) 
as high as 4 mg/mL. The formed NPs by microfluidic process degraded in the presence of enzyme 
(ester linkages) and/or hydrogen peroxide as an oxidizing agent (sulfide bonds), confirmed by DLS 
with the occurrence of large aggregates. As biomedical assessment, the results from cell viability 
experiments with NPs prepared by microfluidic process relied on the nature and amount of surface 
coatings (stabilizers). The use of PEG had enhanced the viability as high as >80% up to 500 g/mL 
of NPs, while the presence of PL-02 had no effect, suggesting that aqueous HDPE-NPs stabilized 
with PEG exhibit less toxicity to HeLa cells. Further, fluorescence imaging results indicate the 












Chapter 3                                                                                               
Dual disassembly and biological evaluation of enzyme/oxidation-




Cancer is one of the leading causes of death worldwide, and tremendous resources have been 
devoted to developing anticancer therapies over the past few decades. While small molecule 
anticancer drugs are effective chemotherapeutics, they typically are not selective to cancer cells 
and cause severe side effects. Further, high doses of drugs must be administered to overcome issues 
with solubility, metabolic reactivity, and/or poor efficacy due to their elimination by kidney 
filtration (or renal clearance) during blood circulation.1-3 Recent efforts have shifted toward 
developing methods for the controlled delivery and release of small molecule anticancer drugs to 
improve their efficacy. Polymer-based drug delivery systems (PDDS),133-136 particularly 
hydrophobic nanoparticulates,89, 90, 137 possess a number of desirable properties such as 
biodegradability, biocompatibility, ability to encapsulate therapeutic agents and deliver them to 
tumor tissues. Upon intravenous injection, well-designed PDDS with excellent colloidal stability 
have prolonged blood circulation; thus offering improved pharmacokinetics and biodistribution to 
tumors via enhanced permeability and retention (EPR),138-140 Followed by their endocytosis into 
cancer cells, drug-loaded PDDS release encapsulated drugs rapidly at predetermined rate, thus 
minimizing side effects and maximizing therapeutic efficacy common to small molecule 
anticancer drugs.  
Stimuli-responsive degradation (SRD) has been explored as a promising platform in the design 
of smart PDDS. SRD involves the incorporation of dynamic covalent linkages into the design of 
PDDS; when needed, response of these linkages to external stimuli changes their chemical and 
physical properties. In such, SRD-exhibiting PDDS which are stable under physiological 
conditions can be dissociated in a controlled fashion as cellular components are provided 
appropriate stimuli thus enabling biodegradation.20, 117, 118, 123, 141 Examples of endogenous stimuli 
include acidic pH, glutathione, reactive oxygen species (ROS), and changes in enzymatic activities, 
while light and temperature are exogenous stimuli.142, 143 Thus, the use of single, dual or multiple 
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stimuli has led to more precise control over the disassembly of smart PDDS.144-146 Among them, 
enzyme-responsive systems are especially promising in that enzymes are great catalysts with high 
selectivity towards specific substrates. Overexpressed disease-associated enzymes including 
esterase act as an effective cellular trigger.33, 147 With growing interest in enzyme-responsive 
platforms, numerous PDDS have been designed with specific peptide linkages that can be cleaved 
in response to enzymes.148-153 However, there are few reports of systems designed to respond to 
esterase.125, 126, 128, 129, 154 In addition to esterase, ROS is found at elevated concentrations in cancer 
cells compared to healthy cells.64, 65 ROS-responsive systems have been developed where ROS-
responsive linkages are cleaved, or hydrophobic/hydrophilic balance is changed upon oxidation.127, 
155-157 Although smart PDDS responding to esterase or ROS are promising, dual stimuli 
enzyme/oxidative-responsive PDDS have not been reported yet to our best knowledge. 
In this work, we developed dual enzyme/oxidation-responsive polyester-based 
nanoparticlulates (DPE-NPs) exhibiting enhanced/controlled release for the tumor-targeting 
intracellular delivery of anticancer drugs. As illustrated in Scheme 3.1, a facile oil-in-water 
emulsion process using hydrophobic polyester (DPE) labeled with both ester and sulfide linkages 
formed aqueous core/shell-type NPs loaded with drugs with an aid of external polymeric stabilizers. 
While the shell provides stealth effect, minimizing immune response and maximizing colloidal 
stability in the blood, the DPE cores are designed to have esterase-responsive ester bonds and 
oxidation-responsive sulfide linkages. Porcine liver esterase and hydrogen peroxide were 
examined here to model the response of DPE-NPs to esterase and ROS. Dual response DPE-NPs 
to these stimuli resulted in main chain degradation or altered polarity, leading to the enhanced 
release of encapsulated doxorubicin (Dox) or hydrophobic model drug (Nile Red). Further, 
aqueous DPE-NPs were assessed as intracellular nanocarriers in vitro in two-dimensional (2D) 




Scheme 3. 1. Schematic illustration of intracellular drug delivery of DPE-based core/shell NPs 
loaded with Dox.  
 
3.2 Experimental   
The detailed instrumentations, TEM analysis, cell viability using MTT assay and polyester 
synthesis are described in the previous chapter. Note that DPE in this chapter indicates HDPE. 
3.2.1 Microscope Imaging 
Two types of microscopes were used. First, HeLa cells and multi-cellular tumor spheroid 
(HeLa and A549) were visualized with Nikon TI-E microscope equipped with LED Heliophors 
with a Photometrics Evolve EMCCD camera. Secondly, endocytosis mechanism of Dox-NPs was 
determined by using inverted Nikon Ti-E Livescan confocal microscope (CLSM) equipped with 




























(Andor). NIS Elements acquisition software was used for both the microscopes. All the images 
were analyzed using Image J (NIH). 
3.2.2 Materials. 
Brij®  S20 (B20), poly(ethylene glycol) (PEG, MW = 6,000 g/mol), esterase from porcine 
liver (18 U/mg; one unit will hydrolyze 1 µmol of ethyl butyrate to butyric acid and ethanol per 
minute at pH 8.0 at 25 ºC), Nile Red (NR), doxorubicin hydrochloride (Dox, -NH3
+Cl- forms, 
>98%), hydrogen peroxide (30% w/w), Bovine Serum Albumin (BSA), and Immunoglobulin G 
(IgG) from human serum (≥95%) from Aldrich, Pierce BCA protein assay kit from Bio-Rad, 
dialysis tubing from Spectrum Labs were purchased and used as received. Dulbecco’s modified 
eagle medium (DMEM), F12K medium, and fetal bovine serum (FBS) from Wisent, phenol-red 
free DMEM from Thermo Fisher Scientific and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) from Promega, and Hoescht 33342 from Invitrogen were 
purchased and used for biological assessment in vitro.  
3.2.3 Stabilizer-assisted NP formation by solvent evaporation method 
An organic solution of the purified and dried DPE (10.8 mg) dissolved in THF (2.3 mL) was 
mixed with an aqueous solution of PEG (10.7 mg) and B20 (0.1 mg) in water (13.6 mL). The 
resulting dispersion was homogenized using sonifier (Branson) for 5 min (amplitude = 15 %, 10 
sec on, 2.5 sec off) and then kept stirred for 24 hrs at room temperature to remove residual THF. 
A stable NP dispersion was formed at 2.0 mg/mL. The resulting mixtures, after being sonified, 
were purified by dialysis with MWCO = 12,000. 
3.2.4 Enzyme/oxidative degradation of NPs 
For oxidation-responsive degradation of NPs in the presence of hydrogen peroxide, aliquots 
of aqueous NP dispersion (2.0 mg/mL, 2.3 mL) were incubated with 1% v/v hydrogen peroxide 
under stirring at room temperature. For enzymatic degradation in the presence of esterase, aliquots 
of aqueous NP dispersion (2.0 mg/mL, 1.8 mL) were incubated with esterase (1 mg), attaining 10 
U. Alternatively, the dispersion was incubated with esterase (2 mg) to attain 20 U. DLS was used 




3.2.5 Preparation of Dox-loaded NPs (Dox-NPs) 
An organic solution containing DPE (12 mg), Dox (1 mg), and Et3N (3.5 µL) dissolved in 
THF (2.8 mL) was mixed with an aqueous solution of B20 (0.6 mg) and PEG (11.5 mg) in water 
(11.7 mL). The resulting mixtures were homogenized using a sonifer (Branson) for 5 min 
(amplitude = 15 %, 10 sec on, 2.5 sec off) and stirred for 24 hrs to remove THF. They were then 
dialyzed over water (1 L) for 6 hrs to remove excess (free) Dox and Et3N, yielding aqueous Dox-
NPs at 2.0 mg/mL. First, the extinction coefficient of Dox was determined in a mixture of 
water/THF (1/4 v/v) using a UV/vis spectroscopy along with Beer-Lambert equation. Then, the 
loading level and loading efficiency of Dox were determined with mixtures consisting of aliquots 
of Dox-NPs (1 mL) mixed with THF (4 mL). The UV/vis spectra were recorded to obtain the 
absorbance at 498 nm. 
3.2.6 Colloidal stability in the presence of proteins 
Aqueous DPE NP dispersion (1 mL, 2 mg/mL) was divided into two aliquots and was mixed 
with BSA (1 mL, 80 mg/mL) and IgG (1 mL, 16 mg/mL) in PBS. As controls, BSA and IgG 
solutions were prepared at the same concentrations. The mixtures were incubated at 37 C for 48 
hrs. Aliquots from each mixture were withdrawn and subjected to centrifugation (10,000 rpm x 15 
min) to precipitate undesirably-formed aggregates. The supernatants were quantitatively analyzed 
using BCA assays according to the Pierce®  BCA assay kit instructions. Briefly, supernatant (25 
µL) was transferred to a 96-well plate and BCA reagent (200 µL) was added to each well. The 
plate was then placed at 37 C for 30 min and the absorbance was measured at λ = 562 nm using 
Powerwave HT Microplate Reader (Bio-Tek). Percentage of free protein was calculated by the 
ratio of the absorbance with NPs to that without NPs (control).  
3.2.7 Esterase-triggered release of Dox from Dox-NPs 
An aqueous mixture consisting of an esterase stock solution (0.24 mL, 2.6 mg/mL) and a Dox-
NP dispersion (0.9 mL, 5.1 mg/mL) in PBS was transferred into dialysis tubing (MWCO = 12,000 
g/mol) and immersed in PBS (40 mL). The UV spectrum of Dox in outer water was recorded at 
indicated time intervals using a UV/Vis spectrometer. For quantitative analysis, Dox (94.8 μg, 




3.2.8 Degradation of Dox upon oxidation 
Dox (0.15 mg) was dissolved in 1% v/v (or 323 mM) hydrogen peroxide solution in water (5 
mL).  Aliquots taken periodically were analyzed by UV/vis spectroscopy to follow the absorbance 
at 498 nm. 
3.2.9 Oxidation-responsive release of NR from aqueous NR-loaded NPs 
First, aqueous NR-loaded NPs were prepared as follows; an aqueous stabilizer solution 
(B20/PEG = 0.05 w/w, 1.1 mg/mL, 10.5 mL) was mixed with an organic solution consisting of 
NR (0.9 mg) and DPE (11 mg) in THF (2.4 mL). The resulting mixture was homogenized for 5 
min and stirred for 24 hrs to remove THF, followed by filtration using 0.85 μm PES filter (Pall 
Corporation) to remove free NR. Then, aliquots of NR-loaded NPs were mixed with hydrogen 
peroxide (1% and 5% v/v) while stirring at 37 ºC. Their fluorescence spectra (ex = 480 nm) were 
recorded periodically to follow FL intensity at 620 nm.  
3.2.10 Cell culture 
HeLa cervical cancer cells were cultured in DMEM (Dulbecco’s modified Eagle’s medium) 
containing 10% FBS (fetal bovine serum) and 1% antibiotics (50 units/mL penicillin and 50 
units/mL streptomycin) at 37 C in a humidified atmosphere containing 5% CO2. A549 cells were 
cultured in F12K media with same supplemental additives as previously mentioned; 10% FBS and 
1% antibiotics. 
3.2.11 Live cell imaging 
HeLa cells were plated at densities of 1× 105 cells/well in a 4-well glass-bottom plate 
(MatTek Corporation) and incubated in media (0.5 mL) at 37 oC for 18 h. The cells were stained 
with Hoechst 33342 dye for 15 min. Then, the cells were washed with PBS three times to remove 
the dye. Phenol red free DMEM medium (0.5 mL) was added to the cells for imaging. Appropriate 
amounts of free Dox or Dox-NPs were added to attain a final Dox concentration of 2.5 μg/mL. 
Imaging was started 10 min post-incubation for 2 hours; images were captured every 10 minutes. 
Cells were placed in a chamber (Live Cell Imaging) at 37 ºC with 5% CO2 and imaged using an 
epifluorescence microscope with a 40x/0.95NA objective. Dox and Hoescht 33342 were excited 
at 405 nm and at 555 nm, respectively. In another set, HeLa cells were incubated with Dox-NPs 
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(encapsulated Dox = 2.5 μg/mL) and free Dox for 12 hrs to examine the intracellular release of 
Dox from Dox-NPs; images were captured after 12 hrs of incubation with the same microscope 
setting. 
3.2.12 Flow cytometry 
HeLa cells were plated at densities of 5×105 cells/well in 6-well dishes and kept at 37 C. 
After 24 h, cells were treated with Dox-NPs (48.6 L, encapsulated Dox = 2.5 g/mL) for either 
30 min or 12 h. After, the cells were washed with DMEM and treated with trypsin. The cells were 
suspended in DMEM (500 L) for flow cytometry measurements using a FACSCanto II flow 
cytometer (BD Biosciences) and FACSDiva software (BD Biosciences). 
3.2.13 Multi-cellular tumor spheroids 
Multi-cellular tumor spheroids (MCTS) were generated from HeLa and A549 cells in 96-
well plates (BioLite, Thermo Scientific). Wells were coated with 1.5% agarose (Biotechnology 
Grade, BioShop), then seeded with 500-1000 cells in 150 µl of growth medium, which were left 
to aggregate with gravity at 37 °C and 5% CO2. MCTS were grown for 6 to 10 days, and were 
monitored daily using an Inverted Invertoskop 40 C light microscope. Once MCTS formation 
was confirmed, they were transferred into 24-well plates coated with agarose in 2 mL of growth 
medium. MCTS were incubated with Dox-NPs (encapsulated Dox = 1.6 μg/mL), free Dox (1.6 
μg/mL) or DPE-NPs (270 μg/mL; control) for 4 days to compare Dox penetration. Images of the 
spheroids were acquired using the epifluorescence microscope with 4x objective; Dox was 
excited at 488 nm. Quantitative analysis of the entire surface area of each spheroid was measured 
and normalized to their initial values at time = 0, thereby giving the fluorescence intensity 
relative to the first values. 
3.2.14 Cellular uptake of Dox-NPs 
HeLa cells were plated on 25 mm round coverslips (No. 1.5) at 40-50% confluency and kept 
at 37 ºC with 5% CO2 using a heated chamber (Tokai Hit). Cells were pre-treated for 1 hr with 
(i) 100 μM Genistein (GEN) to block caveolae-mediated endocytosis, (ii) 5 μM Chlorpromazine 
Hydrochloride (CPZ) to block clathrin-dependent receptor-mediated endocytosis, or (iii) 
100 μM Genistein and 5 μM Chlorpromazine Hydrochloride in combination to block both 
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pathways simultaneously. Cell nuclei were stained with Hoechst 33342 dye prior to imaging. 
The round coverslips were then placed in a 35 mm Chamlide magnetic chamber (Quorum).  
Cells were imaged for 1 hr before and after treatment with a final concentration of 
encapsulated Dox = 2.5 μg/mL. Live imaging was performed on CLSM using 60x/1.4NA oil 
immersion objective. Dox and Hoescht 33342 were excited at 405 nm and at 488 nm, 
respectively. The settings were kept the same for control cells and each treatment. Z-stacks of 0.5 
µm were taken every 5 minutes. 
 
3.3 Results and Discussion 
3.3.1 Preparation of DPE and DPE-based NP colloids 
Figure B.1a illustrates our approach utilizing a base-catalyzed thiol-ene addition to 
synthesize a dual enzyme and oxidation-responsive polyester (DPE) containing both sulfide and 
ester linkages on the backbone. This step-growth polyaddition was designed with a stoichiometric 
balance of thiol to methacrylate group as a 1/1 mole ratio of DSH to EGDMA in the presence of 
triethylamine a base in DMSO, ensuring the synthesis of relatively high molecular weight DPEs. 
They were then purified with precipitation from cold methanol to remove unreacted monomers 
and catalysts. 1H-NMR analysis in Figure B.1b confirms the structure of the DPE; however, the 
determination of the number of repeating units by end-group analysis was not strightforward. Its 
molecular weight as the number average molecular weight (Mn) was determined to be 17 kg/mol 
with molecular weight distribution as broad as Mw/Mn = 1.5, by GPC (Figure B.1c).  
DPE is hydrophobic, and thus needs external stabilizers to form colloidally-stable NPs in 
aqueous solution. To prepare aqueous NPs, combined stabilizers consisting of PEG and B20 were 
empolyed. PEG is biocompatible and FDA-approved for clinincal use; has low cytotoxicity; 
provides excellent sheath effect; and prevents nonspecific protein adsorption.158, 159 However, PEG 
used here has relatively high molecular weight with MW = 6,000 g/mol and thus has low ability 
to reduce the surface tension of water due its tendency to hydrophilicity.160, 161 Although PEG can 
be used to prepare small and stable NPs by microfluidic process due to rapid mixing, PEG does 
not act as an effective stabilizer to form NPs in the desired size range by using solvent evaporation 
method. To circumvent this problem, a mixed stabilizer system was used by adding PEG and B20. 
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B20 has a relatively small molecular weight surface-active agent consisting of the short chains of 
hydrophilic PEG (MW = 800 g/mol) and a hydrophobic stearyl group.162 The addition of B20 to 
the PEG stabilizing system allowed for the synthesis of a colloidally-stable DPE-NP dispersion. 
Figure 1a  shows a DLS diagram of the formed colloids in the presence of PEG/B20 stabilizers 
under the conditions of DPE = 0.9 mg/mL, (PEG+B20)/DPE = 1/1, and B20/PEG = 5% (by 
weight) on toal stabilizers. The formed NPs had a diameter = 99 ± 1 nm (by volume) with size 
distribution as narrow as PDI = 0.11. TEM analysis indicates the NPs have a diameter = 116 ± 12 
nm in dehydrated states (Figure 3.1b).   
  
Figure 3. 1. DLS diagram (n = 3) (a) and TEM image (n = 30) (b) of aqueous DPE NP colloids 
with an aid of mixed PEG/B20 stabilizers. 
 
3.3.2 Enzyme and oxidation-responsive disassembly 
The formed DPE-NPs contain both sulfide and ester linkages in their hydrophobic cores. The 
ester linkages can be cleaved in the presence of esterase (an enzyme that reacts with ester bonds), 
causing destabilization of the NPs. Further, the sulfide linkages can be oxidized to the 
corresponding sulfoxide or sulfone groups in response to an oxidizing agent such as hydrogen 
peroxide. This oxidation process could change the hydrophobic/hydrophilic balance of PE chains, 
causing distabilization of the NPs.  
To examine their enzyme-responsive disassembly, aqueous NPs were mixed with 10 U 
esterase (Figure 3.2a). After 7 hrs of incubation with enzyme, both DLS diagram and TEM image 
show the multimodal distribution of NP sizes, including large aggregates. In comparison, a control 
experiment was conducted in parallel with an aqueous solution of esterase only (without NPs). No 
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significant change in size distribtion of esterase was observed over 1 day (Figure B.2). This result 
suggests that changes in the size distribution of colloids is attributed to their destabilization in 
response to the enzymatic reaction, possibly due to the cleavage of ester linkages in response to 
esterase.  
Oxidation-responsive disassembly was followed with 1% hydrogen peroxide. As seen in 
Figure 3.2b, both DLS and TEM images show that the NPs decreased in size with the diameter 
59 ± 2 nm after 48 hrs of incubation (Figure 3.2b). Similar result of decrease in NP sizes in 
response to hydrogen peroxide has been reported.163 Such a change in size distribution could be 
due to the oxidation-response of sulfide linakges to the corresponding sulfoxides and sulfones, as 
described in the report where 1H-NMR was used to quantively analyze the oxidative degradation 
of poly(carbonate-thioether) in the presence of hydrogen peroxide.164  
 
 
Figure 3. 2. DLS diagrams (by volume %) and TEM images of aqueous DPE-NPs in the 
presence of 10 U esterase incubated for 7 hrs (a) and 1 % hydrogen peroxide incubated for 43 hrs 
(b) at 0.1 mg/mL and pH = 7.2.  
 
3.3.3 Preparation of Dox-loaded NPs 
To assess the use of DPE-NPs as tumor-targeting intracellular drug delivery nanocarriers, 
Dox was encapsulated in the NPs. A mixure consisting of an organic solution of DPE and Dox 
with an aqueous solution of stabilizers was placed in dialysis tubing (MWCO = 12,000 g/mol) and 
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dialyzed against water for 6 hrs. This procedure allows for the removal of excess Dox and Et3N, 
yielding colloidally-stable aqueous Dox-NPs at a concentration of 2.0 mg/mL. The capacity and 
efficiency of loading Dox in NPs was analyzed. The extinction coefficient of Dox in a mixture of 
water/THF at 1/4 v/v was determined to be 8,700 M-1 cm-1 (see Figure B.4 for overlaid UV spectra 
of Dox and linear progression of absorbance at max = 498 nm over various concentrations). An 
aliquot of aqueous Dox-NPs was dissolved in a mixture of water/THF = 1/4 v/v and their UV 
spectrum were recorded (Figure 3.3a). Using the Beer-Lambert equation with the predetermined 
extinction coefficient of Dox in water/THF = 1/4 v/v, the loading level of Dox was 3.6% (weight 
of the Dox/weight of polyester) and encapsulation efficiency was 64% (weight of encapsulated 
Dox/weight of initially added Dox). DLS analysis showed that the diameter of Dox-loaded NPs 
was 144 ± 1 nm, which was larger than that of the empty NPs. Further, Dox-NPs had a monomodal 
distribution with no evidence of significant aggregation (Figure 3.3b). 
  
Figure 3. 3. UV/Vis spectrum (a) and DLS diagram (b) of aqueous Dox-NPs at 2.0 mg/mL. 
 
3.3.4 Colloidal stability of Dox-NPs 
The shelf-life colloidal stability of aqueous colloids was first evaluated using DLS. Their 
diameter was unchanged with no precipitation at room temperature over 330 days suggesting 
excellent colloidal stability (Figure B.5a). Next, the non-specific interaction of Dox-NPs with 
serum (plasma) proteins was examined. Serum proteins can form a “protein corona” around NPs, 


































which results in their rapid elimination from blood circulation and is highly undesirable.165, 166 Two 
of the more abundant proteins in blood were examined: BSA (35 – 52 g/L) and human IgG (8 – 
16 g/L). Aliquots of Dox-NPs were incubated with BSA (40 g/L) and IgG (8 g/L) in PBS at pH = 
7.2 for 48 hrs. They were centrifuged to remove aggregates formed by undesired interactions 
between NPs and proteins, then the supernatants were analyzed using BCA assays to quantify the 
interaction of NPs with proteins. As Figure B.5b shows, both BSA and IgG proteins in the 
supernatants were determined to be >90%. This result suggests that there was no significant 
interaction of NPs with these common serum proteins, and thus the NPs should have excellent 
colloidal stability in circulation. 
3.3.5 Enhanced release of encapsulated Dox and model drug 
The Dox-NPs were examined for their ability to release in response to enzyme and oxidation. 
First, enzyme-responsive enhanced release of Dox from Dox-NPs was examined using UV/Vis 
spectroscopy. An aliquot of Dox-NPs was placed in dialysis tubing (MWCO = 12 kDa) and 
submerged in PBS containing 10 U or 20 U esterase. Samples were taken periodically to record 
UV spectra over time (Figure B.6). Then, the UV absorbance at max = 498 nm was followed to 
investigate %Dox release. As seen in Figure 3.4, <20% Dox was released from Dox-NPs in the 
absence of esterase. In the presence of esterase, the backbone ester linkages should be targeted, 
causing destabilization (or disintegration) of Dox-NPs to enhance the release of Dox. The released 
Dox molecules should diffuse through the dialysis tubing into the outer water and thus UV 
absorbance of Dox in outer water increases. Compared with other supramolecular nanostructures 
(peptide amphiphile-drug conjugate),167 where the change in esterase concentration does not have 
any effect, Dox release occurred in the presence of 10 U esterase, and was faster in the presence 
of 20 U esterase. For example, %Dox reached to as high as 85% with 20 U esterase, compared to 




Figure 3. 4. Release profile in short-term (a) and long-term (b) time scale of Dox from Dox-NPs 
in the absence and presence of 10 U and 20 U esterase at pH = 7.2. Each sample was measured 
three times. 
 
The oxidation-responsive release of Dox from Dox-NPs in response to hydrogen peroxide was 
determined. However, due to the instability of Dox in hydrogen peroxide (1% v/v), the 
experimental approach had to be modified. As seen in our control experiment where Dox was 
incubated with hydrogen peroxide, the absorbance of Dox decreased gradually over the incubation 
time (Figure B.7). A hydrophobic model for anti-cancer drugs is Nile Red (NR), which is stable 
for at least 170 h in hydrogen peroxide (5% v/v).67 Thus, NR-loaded NPs were used as an 
alternative approach to monitor oxidation-responsive release in the presence of hydrogen peroxide 
using fluorsecence spectroscopy. This method can determine changes in the fluorescence intensity 
of NR in different conditions, which would change due to its low solubility in water. NR 
fluorescence is intense when encapsulsted in hydrophobic cores. However, the intensity 
significantly decreases when NR molecules are released and exposed to water as a consequence of 
the destabilization of NR-loaded NPs.168, 169 
Here, the solvent evaporation method was used to prepare aqueous NR-loaded NPs (NR-NPs) 
with a diameter = 153 nm (Figure B.8). Aliquots were incubated with 1% and 5% hydrogen 
peroxide and their emission spectra were followed over time (Figure B.9). In the absence of 
hydrogen peroxide, the fluorescence intensity of NR-NPs at 620 nm remained unchanged, 
suggesting that NR was not released or photobleached (Figure 3.5a). In the presence of hydrogen 
peroxide, the fluorescence intensity decreased with kinetics that correlated with changes in the 











































concentration of hydrogen peroxide (Figure 3.5b). For example, the intensity rapidly decreased to 
5% within 8 hrs in 5% hydrogen peroxide. Interestingly, there was an increase in intensity in 1% 
hydrogen peroxide (Figure 3.5b). This unusual phenomenon could be attributed to self-quenching 
of NR molecules confined in small-sized NR-loaded NPs. Upon destabilization of NR-loaded NPs 
in response to hydrogen peroxide, NP cores could swell, resulting in a decrease in self-quenching 
of NR molecules. After longer incubation, the fluorescence intensity decreased, likely due to 
further destabilization of NPs.170, 171 In another analysis, the emission wavelength of maximum 
fluorescence intensity (em,max) was monitored. As seen in Figure 3.5c, the em,max increased from 
620 nm to 640 nm (max) over the incubation time. This increase in wavelength is similar to the 
decrease in intensity. Given that the em,max of NR is red-shifted when the polarity of the medium 
increases, this increase could arise due to the release of NR molecules from NPs upon oxidative 
degradation which was also supported by the TEM image (Figure 3.5d). These results show that 
NR was rapidily released from encapsulated NR in 5% hydrogen peroxide, and was more slowly 
released in a 1% solution.   
Together, these results show the enhanced release of encapsulated drugs (Dox and NR) from 





Figure 3. 5. Normalized fluorescence (FL) intensity of NR at λem = 620 nm in the mixture of 
aqueous NR-loaded NPs without (a) and with (b) hydrogen peroxide of 1% and 5%; emission 
wavelength of maximum FL intensity of NR in the mixture of aqueous NR-loaded NPs with 
hydrogen peroxide of 1% and 5% (c); and TEM image of NR-loaded NPs incubated with 1% 
hydrogen peroxide (d). Each sample was measured three times (n = 1). 
 
3.3.6 Activity and intracellular uptake in HeLa cells 
The cytotoxicity of DPE-NPs was evaluated on HeLa cervical cancer cells. Dox-loaded NPs 
were compared with empty NPs using a MTT colorimetric assay. As seen in Figure 3.6a, HeLa 
cell viability was >85% in the presence of empty NPs up to 500 g/mL, suggesting non-toxicity 
of empty NPs to HeLa cells. When incubated with NPs loaded with Dox = 1.7 g/mL (equivalent 
to 100 g/mL of Dox-NPs), the viability of HeLa cells decreased to 44% (Figure 3.6b). The 
decreased viability suggests that the proliferation of HeLa cells was inhibited by the Dox-NPs. 
When HeLa cells were treated with the same concentration of free Dox, cell viability significantly 
decreased to <10%, suggesting that free Dox more effectively blocks HeLa cell proliferation over 
48 hours, or two doubling times, compared with Dox-NPs.  




































































































Figure 3. 6. Viability of HeLa cells incubated with different amounts of empty NPs (a) and Dox-
NPs, compared with free Dox, (b) for 48 hrs determined by an MTT assay. Data are presented as 
the average ± standard deviation (n = 6). 
 
Next, the intracellular localization of Dox-NPs was explored using fluorescence 
microscopy. Figure 3.7a shows fluorescence images of HeLa cells 10 min (t = 0) and 2 hrs after 
incubation with free Dox or Dox-NPs. The nuclei were stained with Hoechst 33342, shown in blue, 
and Dox fluorescence is shown in red.  
Dox fluorescence increased with time in cells treated with free Dox or Dox-NPs. However, 
Dox was seen in the nuclei in cells treated with free Dox, while Dox was in the perinuclear region 
rich in endomembrane networks in cells treated with Dox-NPs. Therefore, the NPs likely enter 
cells via endocytosis and traffic to the endomembrane system, where their release may be more 
highly controlled vs. free Dox molecules. Followed by the accumulation in the perinuclear region, 
Dox accumulated in the nuclei after 12 hrs of incubation. This is ascribed to the intracellular release 
of Dox from Dox-NPs (Figure B.10). 
The intracellular accumulation of Dox was also monitored using flow cytometry. HeLa 
cells were analysed using flow cytometry after 30 min and 12 hrs of incubation with free Dox or 
Dox-NPs. As shown in Figure 3.7b, the histogram for free Dox was shifted to higher fluorescence 
intensity, compared with Dox-NPs after 30 min of incubation. After 12 hrs, the histogram for Dox-
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are more obvious in Figure 3.7d-e. While there was only a slight increase in intensity for free Dox 
between 30 min and 12 h of incubation, there was a significant increase in intensity for Dox-NPs. 
This result suggests that the internalization of free Dox occurs very rapidly, but reaches a threshold 
with no further internalization. In contrast, the internalization of Dox-NPs gradually increases over 
time with a greater threshold. 
  
Figure 3. 7. Time-lapse fluorescence microscopy images of HeLa cells incubated with Dox-NPs 
(encapsulated Dox = 1.6 µg/mL), compared with free Dox (2.5 g/mL), for 2 hrs (a) as well as 
their histograms from flow cytometry after 30 min (b) and 12 hrs (c) of incubation and their 
comparison of free Dox-NPs (d) and Dox (e) over incubation time. Note that the images in red 
color (Dox) were processed differently for free Dox and Dox-NPs due to low signal from free 
Dox and the high signal from Dox-NPs. For all experiments, the amount of Dox-NPs was 
designed to have the encapsulated Dox whose concentration was kept to be 2.5 g/mL. (Scale 
bar = 30 µm). 
 
3.3.7 Uptake by cells in multicellular tumor spheroids 
Multicellular tumor spheroids (hereafter referred to as spheroids) grown from cultured cells in 
vitro have properties that mimic solid tumors in vivo, and thus serve as a model to predict the 
ability of drug-loaded NPs to penetrate tumors.172 Here, HeLa cells were induced to form spheroids 
and incubated with Dox-NPs or free Dox at 1.6 μg/mL, or empty DPE NPs as a control for 4 days. 








































fluorescence intensity between Dox-NPs and free Dox. Further quantitative analysis in Figure 
3.8b-c indicates that Dox-NPs show a sharp increase in fluorescence within 6 hrs; and upon further 
incubation, the signal steadily increased. After 4 days of incubation, spheroids with Dox-NPs had 
intensities that were five times greater than spheroids with free Dox. These results suggest that 
Dox-NPs are superior in their ability to penetrate HeLa spheroids compared with free Dox. Thus, 
the controlled uptake and increased threshold of Dox-NPs shown in Figure 3.8 could contribute to 
an overall increased efficacy of uptake at the multicellular level. To determine if Dox-NPs can 
also efficiently penetrate spheroids made from other cell types, a similar experiment was 
performed using spheroids made from A549 lung cancer cells (Figure S11). The uptake of Dox-
NPs in A549 spheroids was greater than free Dox, suggesting that the NPs enhance uptake with 
multiple cancers.  
  
Figure 3. 8. Florescence microscope images of HeLa spheroids incubated for 4 days with Dox 
NPs (encapsulated Dox = 1.6 µg/mL), free Dox (1.6 µg/mL), and empty DPE-NPs (270 µg/mL) 
as a control (a). Quantitative analysis of florescence intensity of the spheroids after short term 
(24 hrs) (b) and long term (4 days) treatments (c). Each value was normalized by their initial 
value. *Note that the images were processed differently for free Dox and Dox-NPs due to low 





3.3.8 Endocytic uptake of Dox-NPs in HeLa cells 
Polymer-based or inorganic NPs can be internalized through several pathways such as clathrin- or 
caveolae-mediated endocytosis, and macropinocytosis.173-175 As shown in Figure 3.9, Dox-NPs 
were visualized in the endomembrane system, supporting that they were taken into cells via one 
of these mechanisms. To gain insight into the mechanism of entry for the DPE NPs, HeLa cells 
were incubated with Dox-NPs after being treated without (control) or with chlorpromazine, 
genistein or a combination of both inhibitors. It has been reported that chlorpromazine inhibits 
clathrin-mediated endocytosis,176 while genistein inhibits caveolae-mediated endocytosis.177 Thus, 
blocking the pathway that mediates the uptake of Dox-NPs should result in no fluorescence signal 
inside cells. Figure 9a shows the fluorescence images of HeLa cells treated with Dox-NPs for 1 hr. 
The red color represents the fluorescence Dox signal, while blue shows the nuclei. Figure 9b shows 
the quantitative analysis of Dox fluorescence intensity for each treatment normalized to maximum 
intensity for control (no inhibitors) over 1 hr. While control cells reached a maximum of 100% of 
normalized intensity after 1 hour, this signal was reduced to 50% after treatment with 
chlorpromazine and remained at 0% after genistein treatment, or when treated with both inhibitors. 
These results suggest that caveolae-mediated endocytosis is the dominant pathway for the 
internalization of Dox-NPs into HeLa cells. Furthermore, the results implicate the reason why 
Dox-NPs exhibit relatively less cytotoxicity, compared with free Dox, although they had greater 
cellular uptake based on flow cytometry results. Clathrin-mediated endocytosis and 
macropinocytosis carry NPs to lysosomes, which are acidic pH (4.5-5.5) and have degradative 
enzymes. Under these conditions, the NPs could be degraded, resulting in enhanced release of 
encapsulated Dox. On the other hand, caveolae-mediated endocytosis carries caveolar vesicles to 
caveosomes; thus the release of Dox is delayed through this endocytosis mechanism.174, 178 
However, the controlled release of Dox from NPs could be more beneficial over longer periods 
time in the context of tumors in vivo, as the capacity for their uptake is higher, this could result in 




Figure 3. 9. FL images of single cell incubated with Dox-NPs in the absence (control) and 
presence of chlorpromazine (CPZ, inhibiting clathrin-mediated endocytosis), or genistein (GEN, 
inhibiting caveolae-mediated endocytosis), or both inhibitors (a) and quantitative analysis of FL 
intensity of Dox in the perinuclear region normalized with maximum FL intensity of control 
system (no inhibitors) over 1 hr (b) (scale bar = 10 µm). 
 
3.4 Conclusion   
Dual enzyme and oxidation-responsive DPEs with ester and sulfide linkages on their 
backbones was synthesized by a thiol-ene polyaddition reaction. DPEs were fabricated into 
aqueous DPE-NP colloids with a diameter = 99 nm, which were relatively non-toxic to HeLa cells 
up to 750 g/mL. They were stable and exhibited prolonged colloidal stability when kept for long 
periods of time on the shelf, or in the presence of serum proteins to mimic physiological conditions. 
The NPs disassembled successfully in the presence of esterase and hydrogen peroxide, upon 
cleavages of the ester linkages and oxidation of the sulfide linkages, respectively, as confirmed by 
DLS analysis. Such dual stimuli-responsive degradation enabled the enhanced and controlled 
release of encapsulated Dox (clinical anticancer drug) and NR (fluorescent dye as a model 
hydrophobic drug) from NPs. The results showed that Dox-NPs effectively inhibited the 
proliferation of HeLa cells, supporting their ability to release Dox in cells. Excitingly, data from 
HeLa or A549 cells grown in 2D or 3D spheroids showed that Dox-NPs were internalized with 
higher thresholds compared to free Dox. Further, Dox-NPs appeared to enter cells predominantly 
by caveolae-mediated endocytosis, which would protect them from degradation in the lysosomes 
























































and permit more controlled release. These results suggest that aqueous NPs are excellent 
candidates as intracellular nanocarriers for the efficient delivery of anti-cancer therapeutics to 




















Chapter 4                                                                                                         
Conclusion and Future work 
 
Stimuli-responsive drug delivery is a promising platform for targeted therapy. Among all 
pathology-associated triggers, ROS and esterase are of great interest because the dual responses 
can be beneficial for clinical translation. As a biological catalyst, esterase can cleave ester linkages 
of the esterase-responsive polymers producing small molecules. These small molecules can be 
excreted from the body by renal filtration rendering biocompatibility even after the delivery of the 
drug. However, the responsive components are embedded in the core of the nanocarriers to prevent 
premature release of the drug. Therefore, the cleavages of ester linkages can be delayed due to the 
size of esterase; the esterase penetrates slowly into the core part of the nanocarriers.40, 179 On the 
other hand, ROS, such as H2O2, can easily reach the core part of the nanocarriers since they are 
small molecules. Therefore, they may act synergistically to initiate the release of therapeutic agents 
and reduce toxicity in vivo.  
Facile and efficient thiol-ene click type reaction was utilized to synthesize hydrophobic 
polyester having oxidation-responsive sulfides and esterase-responsive esters. Chapter 2 explores 
the feasibilities to tune the size of DPE-based NPs using microfluidic method. Choice of 
appropriate stabilizer is required to produce ideal nanocarriers for cancer therapy. PEG and PL02, 
for instance, have been used as model stabilizers to study DPE-NPs. The NP sizes were 
successfully controlled from 50 - 150 nm by changing the formulation and microfluidic 
parameters. Destabilization of the DPE-NPs in the presence of esterase and H2O2 indicated the 
cleavage of ester linkages and oxidation of sulfide linkages. Results from in vitro experiments 
show that the PEG improved cytotoxicity and cellular uptake. The use of DPE-NPs prepared by 
using PEG can be further assessed as intracellular nanocarriers. 
Chapter 3 describes the assessment of dual enzyme and oxidation-responsive polyester 
formulation as intracellular nanocarriers using Dox. Dox was incorporated into DPE-NPs 
stabilized with the PEG and Brij S20. The mixed stabilizer system allows for the preparation of 
smaller and more uniform DPE-NPs. Dox-loaded DPE-NPs (Dox-NPs) had excellent colloidal 
stability and exhibited an enhanced release of Dox upon introduction of esterase and H2O2. 
Furthermore, enhanced antitumor activity of the Dox-NPs in HeLa cells was confirmed by MTT 
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assay. The results from flow cytometry, CLSM and fluorescence microscopy demonstrated that 
the Dox-NPs possess desired properties as intracellular nanocarriers for cancer therapy with an 
excellent cellular uptake capability.  
Overall, stimuli-responsive platform in conjunction with polymeric surfactant enabled the 
development of a nanoparticulate formulation for cancer therapy. Although the current design 
showed promising results, a few suggestions that could lead to an improvement. First, microfluidic 
instrument can be used to encapsulate Dox. Controlling the mixing rate can influence drug loading; 
the variation of microfluidic parameters can increase drug loading capacity and encapsulation 
efficiency. Second, branched polyesters consisting of esters and sulfides can be synthesized and 
characterized. Branched polyesters are relatively more hydrophobic than the linear polyester of 
similar molecular weight. This feature may improve encapsulation efficiency of hydrophobic 
drugs. It would be also interesting to compare the release kinetics since physical properties of the 
hydrophobic block, such as glass transition temperature (Tg), can affect the release rate.
180 Third, 
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Figure A. 1. DLS diagram of aqueous HDPE-NPs prepared in the presence of PEG. NP 
concentration = 7 mg/mL (a) and 14 mg/mL (b). Microfluidic conditions: TFR = 12 mL/min, 
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Figure A. 2. DLS diagram of aqueous HDPE-NPs prepared with no stabilizers. Microfluidic 
conditions: TFR = 12 mL/min, FRR = 1/3, and NP concentration = 3.4 g/mL.  
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Figure A. 4. DLS diagram (a) and sizes and size distribution of HDPE-NPs stabilized by using 
PL02 (b). Microfluidic conditions: TFR = 12 mL/min, FRR = 1/1, PL02/HDPE = 0.1/1 (wt/wt), 
and NP concentration = 3.7 mg/mL. 
 
  






















































Figure B. 1. Synthesis (a), 1H NMR spectrum (b), and GPC trace (c) of a dual enzyme and 
oxidation-responsive polyester (DPE) through a base-catalyzed thiol-ene polyaddition. 
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Figure B. 3. 1H-NMR spectra of DPE-NPs before and after treatment with 1% hydrogen 
peroxide treated with GPC trace of DPE. 
 
 
Figure B. 4. Overlaid UV/vis spectra of Dox (a) and plot of absorbance at 498 nm over Dox (b) 
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Figure B. 5. Colloidal stability of aqueous Dox-NPs on shelf (a) and in the presence of BSA (40 






























































Figure B. 6. Overlaid UV/vis spectra of Dox in outer water over time. 
  
 
Figure B. 7. Overlaid UV/vis spectra (a) and evolution of absorbance at 498 nm (b) of free Dox 
incubated with 1% hydrogen peroxide in aqueous solution.  
 
  





































































Figure B. 9. Overlaid emission spectra of aqueous NR-loaded NPs incubated without (a) and 
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Figure B. 10. Epifluorescence microscopy images of HeLa cells incubated with Dox-NPs (2.5 
µg/mL), compared with free Dox (2.5 µg/mL) for 12 hrs. Arrows indicate the localization of 
Dox-NPs and free Dox in HeLa cell nuclei. *Brightness and contrast were adjusted to show the 
internalization of the Free Dox. (scale bar = 30 µm) 
 

























Figure B. 11. Florescence microscope images of A549 MCTS incubated for 4 days with Dox 
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